|
|
|
|
|
|
|
|
|
06.05.26 - 12:03
|
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance (Business Wire)
|
|
|
– Delivered double-digit reported and constant-currency revenue growth
– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)
– Received U.S. Food and Drug Administration premarket approval for aura6000 System to treat moderate to severe obstructive sleep apneaLONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance.
Financial Summary and Highlights(1)
First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period
First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98
First-quarter net cash provided by operating activities of $15.2 million and adjusted free cash flow of $3.8 million
Raised full-year 2026 revenue growth range by 100 basis points to 7.0% to 8.0% on a constant-curr...
|
|
|
25.03.26 - 14:06
|
LivaNova to Announce First-Quarter 2026 Results (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call.
The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 946097. A replay will be available on the Investors section of the LivaNova website immediately following the event.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Through ingenious medical solutions ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.02.26 - 12:06
|
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance (Business Wire)
|
|
|
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025
– Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25
– Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration
– Received U.S. Food and Drug Administration approval for cloud-based digital health platformLONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance.
Financial Summary and Highlights(1)
Fourth-quarter revenue of $360.9 million increased 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis as compared to th...
|
|
|
|
|
|
|
20.01.26 - 15:03
|
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call.
The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 901145. A replay will be available on the Investors section of the LivaNova website immediately following the event.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Thro...
|
|
|
03.12.25 - 15:06
|
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting (Business Wire)
|
|
|
Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy
LONDON--(BUSINESS WIRE)--$LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses.
“At the heart of LivaNova's purpose as a Company, we aim to help patients reclaim their lives by improving global access to epilepsy treatment and supporting better outcomes,” said Stephanie Bolton, LivaNova President, Global Epilepsy. “Our CORE-VNS study confirms the proven benefits of VNS Therapy in patients with Drug-Resistant Epilepsy and reveals there are benefits of use earlier in the...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
